Altium Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Altium Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-315,070	Closed	-$1.13M	–	116
2022 Q4	$1.13M	Buy	+315,070	New	+$1.37M	0.57%	42
2022 Q1	–	Sell	-116,000	Closed	-$3.78M	–	154
2021 Q4	$3.78M	Sell	116,000 -11,241	-9%	-$455K	1.04%	37
2021 Q3	$5.69M	Buy	127,241 +19,547	+18%	+$954K	1.49%	19
2021 Q2	$5.87M	Buy	107,694 +95,024	+750%	+$5.62M	1.36%	18
2021 Q1	$948K	Buy	+12,670	New	+$1.32M	0.26%	111

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Altium Capital Management's SYRS Position: Q1 2023 in Review

Altium Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2023, closing a stake of 315,070 shares — an estimated $1.13M sold.

Altium Capital Management first reported a position in SYRS in Q1 2021 and held it in 5 quarters. The position peaked at $5.87M in Q2 2021. 59 funds tracked by Wall St. Rank hold SYRS as of Q1 2023.

Altium Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Altium Capital Management sold 315,070 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $1.13M.
Altium Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Altium Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5.87M in Q2 2021.
59 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.